Tero Aittokallio profile picture
Tero
Aittokallio
InFLAMES Flagship
Docent, Faculty of Science
PhD

Contact

+358 29 450 4321
+358 50 350 9623
Vesilinnantie 5
20500
Turku

Biography

Tero Aittokallio received his PhD in Applied Mathematics from the University of Turku in 2001, under the supervision of Prof. Mats Gyllenberg. He then did his post-doctoral training in the Systems Biology Lab at the Institut Pasteur (2006-2007), with Dr. Benno Schwikowski, where he focused on network biology applications using high-throughput experimental assays and network analysis tools such as Cytoscape. In 2007, Dr. Aittokallio launched his independent career as a principal investigator in the Turku Biomathematics Research Group, where he received a five-year appointment as an Academy of Finland Research Fellow (2007-2012). Tero Aittokallio joined Institute for Molecular Medicine Finland (FIMM) as EMBL Group Leader in the fall of 2011, and was selected as Professor of Statistics and Applied Mathematics at University of Turku in 2015.

Teaching

Computational statistics.

Scientific computing.

Research

Aittokallio's research group focuses on developing and applying integrated computational-experimental approaches to tackle biomedical questions, such as how genes function as interaction networks to carry out and regulate cellular processes, how alterations in these networks contribute to complex traits, such as human diseases, and where and how in the disease network one should target to optimally inhibit the disease phenotypes, such as tumor growth.

Publications

Sort by:

A community effort to assess and improve drug sensitivity prediction algorithms (2014)

Nature Biotechnology
Costello JC, Heiser LM, Georgii E, Gonen M, Menden MP, Wang NJ, Bansal M, Ammad-ud-din M, Hintsanen P, Khan SA, Mpindi JP, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K, Collins JJ, Gallahan D, Singer D, Saez-Rodriguez J, Kaski S, Gray JW, Stolovitzky G
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice (2013)

Cell Death and Disease
Kakkola L, Denisova OV, Tynell J, Viiliainen J, Ysenbaert T, Matos RC, Nagaraj A, Ohman T, Kuivanen S, Paavilainen H, Feng L, Yadav B, Julkunen I, Vapalahti O, Hukkanen V, Stenman J, Aittokallio T, Verschuren EW, Ojala PM, Nyman T, Saelens X, Dzeyk K, Kainov DE
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))